PointState Capital’s GSK GSK Stock Holding History

PointState Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-44,229	Closed	-$2.41M	–	59
2022 Q2	$2.41M	Buy	+44,229	New	+$2.44M	0.06%	51
2022 Q1	–	Sell	-88,000	Closed	-$4.85M	–	94
2021 Q4	$4.85M	Sell	88,000 -78,800	-47%	-$4.1M	0.08%	90
2021 Q3	$7.97M	Buy	166,800 +30,000	+22%	+$1.51M	0.13%	92
2021 Q2	$6.81M	Buy	+136,800	New	+$6.57M	0.12%	86

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PointState Capital's GSK Position: Q3 2022 in Review

PointState Capital sold out of GSK (GSK) in Q3 2022, closing a stake of 44,229 shares — an estimated $2.41M sold.

PointState Capital first reported a position in GSK in Q2 2021 and held it in 4 quarters. The position peaked at $7.97M in Q3 2021. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

PointState Capital reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
PointState Capital sold 44,229 GSK shares in Q3 2022, an estimated $2.41M.
PointState Capital first reported a position in GSK in Q2 2021 and held it in 4 quarters.
PointState Capital's GSK position peaked at $7.97M in Q3 2021.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.